A Wisconsin pharmaceutical company developing anticancer compounds has raised $1.49 million, according to a regulatory filing.
Quintessence Biosciencescompounds are based on EVade Ribonuclease technology that function by destroying the RNA or ribonucleic acid in cancer cells.
Of the compounds the company is developing, the one that has progressed the most is the QBI-139, which is currently being tested at the University of Texas M.D. Anderson Cancer Center and the University of Wisconsin Carbone Cancer Center. Forty patients have been treated in the company’s first in human trials.
Previously, the company has said that the compound “has shown significant tumor growth inhibition against humanpancreatic, non-small cell lung, prostate and ovarian solid tumors” in vitro and in vivo.
Laura Strong is the president of Quintbio. Strong is a board member of the Wisconsin Biotechnology and Medical Device Association served as the company’s vice president since 2000. A call to Strong was not returned.
[Photo Credit: freedigitalphotos]
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.